Stereoselectivity of binding of α-(N-benzylamino)benzylphosphonic acids to prostatic acid phosphatase

Bioorganic and Medicinal Chemistry Letters

Volumn 18, Issue 16, 2008, Pages 4620-4623

  Vovk, Andriy I ^a   Mischenko, Iryna M ^a   Tanchuk, Vsevolod Yu ^a   Kachkovskii, Georgiy A ^a   Sheiko, Sergiy Yu ^a   Kolodyazhnyi, Oleg I ^a   Kukhar, Valery P ^a  

^a INSTITUTE OF BIOORGANIC CHEMISTRY AND PETROCHEMISTRY   (Ukraine)

Author keywords

Aminophosphonic acid; Binding mode; Inhibition; Molecular modeling; Prostatic acid phosphatase

Indexed keywords

ACID PHOSPHATASE PROSTATE ISOENZYME; PHOSPHONIC ACID DERIVATIVE;

ARTICLE; BINDING AFFINITY; ENANTIOSELECTIVITY; PROTEIN BINDING; STEREOCHEMISTRY;

BENZYLAMINES; CHEMISTRY, PHARMACEUTICAL; DRUG DESIGN; HUMANS; INHIBITORY CONCENTRATION 50; MALE; MODELS, CHEMICAL; MODELS, MOLECULAR; MOLECULAR CONFORMATION; PHOSPHONIC ACIDS; PROSTATE; PROTEASE INHIBITORS; PROTEIN BINDING; PROTEIN TYROSINE PHOSPHATASES; STEREOISOMERISM; THERMODYNAMICS;

EID: 48649105425     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2008.07.021     Document Type: Article

References (21)

1. Bull H., Murray P.G., Thomas D., Fraser A.M., and Nelson P.N. J. Clin. Pathol.: Mol. Pathol. 55 (2002) 65
2. Sharma S., Pirila P., Kaija H., Porvari K., Vihko P., and Juffer A.H. Protein 58 (2005) 29
3. Veeramani S., Yuan T.C., Chen S.J., Lin F.F., Petersen J.E., Shaheduzzaman S., Srivastava S., MacDonald R.G., and Lin M.F. Endocr. Relat. Cancer 12 (2005) 805
4. Quintero I.B., Araujo C.L., Pulkka A.E., Wirkkala R.S., Herrala A.M., Eskelinen E., Jokitalo E., Hellstroöm P.A., Tuominen H.J., Hirvikoski P.P., and Vihko P.T. Cancer Res. 67 (2007) 6549
5. Emlet D.R., Schwartz R., Brown K.A., Pollice A.A., Smith C.A., and Shackney S.E. Br. J. Cancer 94 (2006) 1144
6. Tanaka M., Kishi Y., Takanezawa Y., Kakehi Y., Aoki J., and Arai H. FEBS Lett. 571 (2004) 197
7. Wang Y., Harada M., Yano H., Ogasawara S., Takedatsu H., Arima Y., Matsueda S., Yamada A., and Itoh K. J. Immunother. 28 (2005) 535
8. Taira A., Merrick G., Wallner K., and Dattoli M. Oncology (Williston Park) 21 (2007) 1003
9. Schwender C.F., Beers S.A., Malloy E.A., Cinicola J.J., Wustrow D.J., Demarest K.D., and Jordan J. Bioorg. Med. Chem. Lett. 6 (1996) 311
10. Beers S.A., Schwender C.F., Loughney D.A., Malloy E., Demarest K., and Jordan J. Bioorg. Med. Chem. 4 (1996) 1693
11. Ortlund E., LaCount M.W., and Lebioda L. Biochemistry 42 (2003) 383
12. Kolodiazhnyi O.I., Grishkun E.V., Sheiko S.Yu., Demchuk O., Thoennessen H., Jones P., and Schmutzler R. Tetrahedron: Asymmetry 9 (1998) 1645
13. Kolodiazhnyi O.I., Sheiko S.Yu., and Grishkun E.V. Heteroat. Chem. 11 (2000) 138
14. Kachkovskii G.A., Andrushko N.V., Sheiko S.Yu., and Kolodyazhnyi O.I. Russ. J. Gen. Chem. 75 (2005) 1735
15. Compounds 1a and 1b were prepared by reaction of di[(1R,2S,5R)-menth-2-yl]phosphite or di-endo-bornylphosphite, respectively, with phenylbenzaldimine followed by hydrolysis of corresponding phosphonates. Enantiomeric (1R,2S)- and (1S,2R)-phenyl[(1-phenylethyl)amino]methylphosphonic acids 2a,b were obtained in similar manner by the reaction of di[(1R,2S,5R)-menth-2-yl]phosphite with chiral (S)- and (R)-α-methylbenzylbenzaldimine, respectively. In the case of phosphonic acids 3a,b di[(1R,2S,5R)-menth-2-yl]phosphite was coupled to (R)- or (S)-α-methylbenzyl-p-methoxybenzaldimine. The absolute configurations of enantiomerically pure compounds were determined by comparison of optical rotations with reported values.
16. Luchter-Wasylewska E. A{cyrillic}s{cyrillic}ta Biochim. Pol. 44 (1997) 853
17. Luchter-Wasylewska E. Biochim. Biophys. Acta 1548 (2001) 257
18. 50 value was determined from this curve.
19. Nguyen L., Chapdelalne A., and Chevalier S. Clin. Chem. 36 (1990) 1450
20. McMartin C., and Bohacek R.S. J. Comput. Aided Mol. Des. 11 (1997) 333
21. Pospisil P., Wang K., Al Aowad A.F., Iyer L.K., Adelstein S.J., and Kassis A.I. Cancer Res. 67 (2007) 2197